Telix, Monrol reach agreement on therapeutic isotope supply

June 28, 2021 -- Telix Pharmaceuticals has signed a global clinical supply agreement with Istanbul-based Eczacıbaşı-Monrol Nuclear Products (Monrol) for the supply of no-carrier-added lutetium-177 (Lu-177), a therapeutic isotope used in Telix's portfolio of molecularly targeted radiation products.

Under the terms of the agreement, Monrol will supply the isotope for clinical and commercial use in support of Telix's development programs. The deal builds on an existing agreement the two firms established in 2019 to support a phase III trial of Telix's TLX250-CDx for PET imaging of renal carcinoma, Telix said.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking